NEXTCURE, INC Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
NEXTCURE, INC (NXTC) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.30% for the 12-month period ending 2025-12-31, per its S-4 filed 2026-08-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-08-18
- NEXTCURE, INC effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -0.10%.
- NEXTCURE, INC effective income tax rate reconciliation, other adjustments, percent for fiscal 2018 was 0.30%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2025-12-31 | -0.30% S-4 · filed 2026-08-18 |
| 2024-12-31 | -1.60% S-4 · filed 2026-08-18 |
| 2023-12-31 | -0.10% 10-K · filed 2025-03-06 |
| 2018-12-31 | 0.30% 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |